VEM Vermoegensverwaltung GmbH, the investment vehicle that controls Ulm, Germany-based Ratiopharm, began a “structured sales process” today. The trustees are prepared to sell the company in parts if it provides “better prospects” for the sale, though it would prefer a divestment of the drugmaker as a whole, VEM said in an e-mailed statement. (Ver...)Por otra parte, Pharma Times
coloca en "primera línea de interesados" a Teva, Mylan y Novartis:
"High number" of potential buyers as sale of Ratiopharm begins
18 September 2009
The process of divesting Ratiopharm, the world's fourth-largest generic drugsmaker, owned by the conglomerate formerly run by German billionaire Adolf Merckle, who committed suicide at the start of the year, is underway.
.../...
The sale is expected to raise around 3 billion euros, and the usual suspects – Teva, Mylan and Novartis – as well as other companies who have stated their desire to grow in the generics market, such as Pfizer, GlaxoSmithKline and Sanofi-Aventis.
Entradas
No hay comentarios:
Publicar un comentario